Bone and Joint Infection Clinical Trial
Official title:
Pristinamycin in the Treatment of MSSA Bone and Joint Infection
Staphylococcus aureus represents the leading pathogen implicated in bone and joint infection
(BJI), usually requiring prolonged combination antimicrobial therapy, which may be
particularly challenging in the case of MDR bacteria and/or for patients with multiple drug
intolerance. In the absence of new well-tolerated oral antistaphylococcal drugs, older
antibiotics must be considered, such as the pristinamycin.
However, pristinamycin is not currently licensed for treatment of staphylococcal BJI and
lack of clinical data prevents it from being considered as a reliable alternative
therapeutic option in current guidelines.
The aim of this study is to evaluate pristinamycin (efficacy and tolerance) in the treatment
of MSSA bone and joint infection (BJI).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05421312 -
Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip
|
Phase 4 | |
| Active, not recruiting |
NCT04563325 -
Oral-only Antibiotics for Bone and Joint Infections in Children
|
Phase 4 | |
| Completed |
NCT03627000 -
Microbiological Epidemiology in Patients Experiencing Microbiological or Clinical Failure Following Reimplantation After a 2-stage Exchange Strategy for Hip or Knee Prosthetic Joint Infection
|
||
| Completed |
NCT03311113 -
Adherence to Oral Antibiotics In Patients With Osteoarticular Infections
|
||
| Recruiting |
NCT05753215 -
Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection
|
Phase 2 | |
| Completed |
NCT03209921 -
Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections
|
N/A | |
| Completed |
NCT04418882 -
Septic Management and Outcome of Open Fracture
|
||
| Completed |
NCT05248490 -
Impact of Pharmaceutical Interviews Regarding the Management of Adverse Effects Related to the Antibiotic Therapy Used to Treat Osteoarticular Infections During Return Home
|
N/A | |
| Completed |
NCT03624855 -
Implant-Associated P. Aeruginosa Bone And Joint Infections : Experience In A Regional Reference Center In France
|
||
| Recruiting |
NCT04496024 -
Ofloxacin Concentration-toxicity Relationship in the Elderly
|
N/A | |
| Recruiting |
NCT04933344 -
Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections
|
||
| Recruiting |
NCT04538053 -
BonE and Joint Infections - Simplifying Treatment in Children Trial
|
Phase 4 | |
| Completed |
NCT04373278 -
Infection After Free Fibula Flap Reconstruction of the Mandible: a Retrospective Cohort Study
|
||
| Completed |
NCT03209934 -
Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center
|
N/A | |
| Recruiting |
NCT02817711 -
Lyon BJI Cohort Study
|
N/A | |
| Recruiting |
NCT03611634 -
Consitution Of A Biological Collection From Samples From The Gut Microbiote In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine
|
||
| Completed |
NCT03177369 -
Teicoplanin-based Antimicrobial Therapy in Staphylococcus Aureus Bone and Joint Infection: Tolerance, Efficacy and Experience With Subcutaneous Administration
|
N/A | |
| Recruiting |
NCT04722926 -
Lyon PJI Retrospective Cohort Study
|
||
| Completed |
NCT03852784 -
Osteoarticular Infections With Pneumococcal
|
||
| Recruiting |
NCT03796104 -
Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR
|